Stocktoria

Skye Bioscience, Inc. SKYE

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2014-02-24

Skye Bioscience, Inc. statistics & valuation

Market cap$23.9M
P / B1.2×
Return on capital-289.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
2016201720182019202020212022202320242025
Operating margin (%)
2016201720182019202020212022202320242025
Return on equity (%)
191.90% -1455.40% -145.30% -39.00% -279.30% 2016201720182019202020212022202320242025
Shares outstanding
21.6M 33.6M 133.9M 182.9M 288.1M 476.1M 3.7M 12.3M 36.5M 39.7M 2016201720182019202020212022202320242025
Net debt ($)
2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
-982.80% -555.30% -980.70% 52.70% -245.60% -86.50% -213.80% -315.30% -36.50% -197.50% 2016201720182019202020212022202320242025
Free cash flow margin (%)
2016201720182019202020212022202320242025
Debt / equity (×)
2016201720182019202020212022202320242025
EPS ($)
-$0.17 -$0.11 -$0.16 -$0.05 -$0.03 -$0.02 -$8.77 -$5.37 -$0.73 -$1.41 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Return on assets-197.5%-36.5%-315.3%-213.8%-86.5%-245.6%52.7%-980.7%-555.3%-982.8%
Return on equity-279.3%-39.0%1765.9%647.6%-145.3%-1455.4%191.9%123.3%86.7%109.1%
Current ratio3.3016.320.840.742.463.382.050.120.690.42

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.